register

News & Trends - Pharmaceuticals

Australian pharma divests its generics portfolio

Health Industry Hub | March 6, 2023 |

Pharma News: Australia’s Mayne Pharma announced that it has entered into an agreement with Dr. Reddy’s Laboratories to sell its US retail generics portfolio for US$90 million (~A$133 million).

Following the transaction, Mayne Pharma’s commercial activities will be solely focused on its US women’s health portfolio, (including the recent exclusive licence of three branded women’s health products and a portfolio of prenatal vitamins from TherapeuticsMD, Inc), US dermatology products and its International business.

The sale includes all assets of the US retail generics business unit, comprising a portfolio of 85 generic products and 4 generic pipeline products. For fiscal year ending June 2022, this portfolio generated US$111 million in revenues.

At the closing of the sale, Mayne Pharma and Dr. Reddy’s will enter into a 10-year supply agreement on arm’s length terms for certain products that are manufactured at Mayne Pharma’s facility in Salisbury, South Australia.

Mayne Pharma’s CEO Shawn Patrick O’Brien said “Divesting the retail generics portfolio is an important step forward for the Company as we continue to rationalise our portfolio. With this transaction, we free up working capital, allowing us to more exclusively focus resources on core areas of value for business growth, namely our branded verticals in US women’s health and dermatology. We are creating a leaner company with strong commercial and sales execution capabilities. With this transaction, we move closer to achieving our goal of generating operating cash and returning the business to profitability.”

Dr Reddy’s CEO Erez Israeli said “The portfolio of products acquired from Mayne Pharma is a strategic fit with our growth objectives. The portfolio includes some high entry-barrier products. It also complements our existing portfolio by introducing products focused on women’s health. Our strong balance sheet enables us to acquire products of strategic importance to strengthen our base business and build for long-term growth.”

The transaction is expected to close by the end of fiscal year 2023.


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.